J Korean Soc Pediatr Nephrol > Volume 5(2); 2001 > Article
 Journal of the Korean Society of Pediatric Nephrology 2001;5(2): 109-116.
 소아 스테로이드 의존형 신증후군에서 Levamisole의 치료 효과 한재혁, 이경재, 이영목, 김지홍, 김병길 1연세대학교 의과대학 소아과학교실, 신장질환연구소2연세대학교 의과대학 소아과학교실, 신장질환연구소3연세대학교 의과대학 소아과학교실, 신장질환연구소4연세대학교 의과대학 소아과학교실, 신장질환연구소5연세대학교 의과대학 소아과학교실, 신장질환연구소 The Effect of levamisole in Steroid-Dependent Nephrotic Syndrome in Children Jae-Hyuk Han, Kyoung-Jae Lee, Young-Mock Lee, Il-Hong Kim, Pyung-Kil Kim 1Department of Pediatrics, The Institute of Kidney Disease, Yonsei University, College of Medicine2Department of Pediatrics, The Institute of Kidney Disease, Yonsei University, College of Medicine3Department of Pediatrics, The Institute of Kidney Disease, Yonsei University, College of Medicine4Department of Pediatrics, The Institute of Kidney Disease, Yonsei University, College of Medicine5Department of Pediatrics, The Institute of Kidney Disease, Yonsei University, College of Medicine Share : ABSTRACT Purpose Long- term use of steroid, cyclophosphamide and cyclosporin, which are frequently used in the therapy of SDNS, might cause severe side effects. Recently, the immune-modulator levamisole has been tried as a substitute therapy and it has been reported as a method with less side effects and more effectiveness. We started this research in order to observe the effects of levamisole and compare it to other therapy results. Patients and Methods : We chose 16 steroid dependent nephrotic syndrome children, those who had shown frequent relapse during the immunocompromised therapy period. Mean age was $9.1{pm}1.4$ years in children and the male to female ratio was 15:1. All of subjects were diagonized with MCNS and had received cyclophosphamide or cyclosporin before receiving levamisole. Levamisole at a dose of 2.5mg/kg was used every other day for 1 year and the relapse rate was observed. Results : On average of 14 days after treatment, complete remission was visible in all of the children, and the relapse percentage was $50%$, which represents 8 children, while remaining 8 children representing $50%$ of the cases showed no relapse during treatment. During the levamisole therapy period, tile average relapse rate was reduced significantly from $2.18{pm}0.9/year;to;0.77{pm}0.9/year$(P=0.027). Also the average relapse rate after the therapy was reduced to $1.34{pm}1.1/year$, which was a significant level compared to the level before treatment(P=0.003). There was no significant difference in terms of duration of remission maintenance. Duration of remission maintenance showed an average of $12.2{pm}9.1$ months before the use of levamisole, but it was also $10.1{pm}6.9$ month after therapy. No other side effects such as leukopenia, skin disease and other clinically significant symptoms appeared at all during therapy. Conclusion : The long-term medication of levamisole for the therapy of SDNS children is thought to be able to maintain stable remission by reducing the relapse frequency without causing severe side effects. Further study with a broader range of subjects is required to eluccidate the long-term effects of this treatment. (J. Korean Soc Pediatr Nephrol 2001;5 : 109-16) Key words: Steroid-dependent nephrotic syndrome | Levamisole

 Editorial Office 240, Gimpohangang 1-ro, Gimpo-si, Gyeonggi-do, 10078, Republic of Korea TEL: +82-10-4391-0788   E-mail: chikd@chikd.org Copyright© Korean Society of Pediatric Nephrology.